To investigate the clinical effectiveness of recombinant human GM-CSF(rhGM-CSF;Leucogen ) on the chemotherapy-induced neutropenia, twelve children with malignant solid tumor who had neutropenia after chemotherapy received 250μg/M*/day of
rhGM-CSF
subcutaneouly for 10 consecutive days from the fifth day of next chemotherapy were schedule using the same regimen.
rhGM-CSF significantly increased leukocyte, neutrophil and eosinophil counts on the tenth day of GM-CSF course compared to the control course(p<0.05), but there was no significant difference in the counts of monocyte, lymphocyte, platelet or
hemoglobin(P>0.1). The nadir of leukocyte and neutrophil were significantly higher in GM-CSF course than hose of control course (p<0.05), but there was no significant difference in that of monocyte, lymphocyte, eosinophil, platelet or
hemoglobin(P>0.1).
The duration of chemotherapy-induced leukopenia and neutropenia were decreased significantly in GM-CSF course than those of control course(p<0.05). The duration of antibiotics administration and febrile period during chemotherapy were shorter in
GM-CSF
course without statistical significance. No significant side effect was observed during rhGM-CSF course.
Thses results indicate that rhGM-CSF(Leucogen ) is effective in alleviating the chemotherapy-induced neutropenia of children with malignant solid tumors.
|